Evidence map›Paper›PMID 35468795›Full record

ArticleBMC pulmonary medicine2022

Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation.

Naohisa Urabe, Susumu Sakamoto, Yui Shimanuki, Takumi Kanokogi, Takumi Motohashi, Nanami Anzai, Chiaki Kato, Asuka Yamaguchi, Nozomi Tokita, Sakae Homma and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Co-infection withFrontiers in medicine · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Naohisa UrabeDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Susumu SakamotoDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan. susumu1029@gmail.com.
Yui ShimanukiDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Takumi KanokogiDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Takumi MotohashiDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Nanami AnzaiDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Chiaki KatoDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Asuka YamaguchiDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Nozomi TokitaDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Sakae HommaDepartment of Advanced and Integrated Interstitial Lung Diseases Research, Toho University School of Medicine, Tokyo, Japan.
Kazuma KishiDepartment of Respiratory Medicine, Omori Medical Center, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.
Toho University · JPToho University Omori Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of co-infection with other pathogenic microorganisms after initiation of treatment for Mycobacterium avium complex pulmonary disease (MAC-PD) has not been clearly described. This study sought to clarify the clinical outcomes of co-infection with MAC after antimycobacterial therapy for MAC.

methodsCo-infection status was defined as the detection of pathogenic microorganisms other than MAC in at least two consecutive sputum cultures 6-24 months after initiation of treatment. Chest computed tomography (CT) findings and culture results were compared between co-infection and MAC alone groups.

resultsThe co-infection and MAC alone groups comprised 12 and 36 patients, respectively. The proportion of patients with sputum culture positive for MAC after 24 months of therapy did not differ significantly between the two groups [25% (3/12) vs. 16.7% (6/36); p = 0.671]. The proportion of patients with improved chest CT score after 24 months of starting treatment compared to baseline was significantly lower for the co-infection group than for the MAC alone group [16.7% (2/12) vs. 79.4% (27/34); p < 0.001]. In the co-infection group, median CT score values at 12 and 24 months did not differ from baseline. However, the MAC alone group showed significant improvement at 12 and 24 months compared with baseline.

conclusionsIn the patient group with co-infection of other pathogenic microorganisms after treatment initiation for MAC there was no impact on therapeutic efficacy compared to the MAC alone group. However, therapeutic intervention interfered with improvement in chest CT findings such as nodule formation, bronchiectasis, infiltration, and cavitary lesions.

Indexed as

BronchiectasisCoinfectionLung DiseasesMycobacterium avium-intracellulare InfectionHumansMycobacterium avium ComplexCo-infectionMycobacterium avium complexNontuberculous mycobacteriumPseudomonas aeruginosa

Identifiers

PMID35468795
PMCPMC9036801
OpenAlexW4225260709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.